After years of limited progress in glioblastoma treatment due to high clinical failure rates and industry retreat, renewed interest and funding are driving advancements in therapeutics and trial methodologies. Recent acquisitions by Merck and Jazz Pharmaceuticals include promising candidates and adaptive trial designs targeting this aggressive brain cancer. Nonprofits and investment groups are fostering innovation, marking a gradual shift toward more effective therapies in glioblastoma management.